Diatec Monoclonals AS offers an excellent monoclonal antibody
against human C5b-9, the Terminal Complement Complex (TCC). The
antibody is produced in vitro by the aE11 hybridoma and purified
with protein A to a purity more than 98%.
This antibody recognizes C5b-9, the terminal complement complex (TCC). TCC consist of C5b, C6, C7, C8 and C9 and contains neoantigens that are absent from the individual native components.
aE11 produces monoclonal antibodies against neoantigens of both membrane bound (MAC) and fluid phase (SC5b-9) complexes. This antibody is directed against a neoepitope exposed in C9 when incorporated into the terminal complement complex (TCC)
This antibody recognizes C5b-9, the terminal complement complex (TCC). TCC consist of C5b, C6, C7, C8 and C9 and contains neoantigens that are absent from the individual native components.
aE11 produces monoclonal antibodies against neoantigens of both membrane bound (MAC) and fluid phase (SC5b-9) complexes. This antibody is directed against a neoepitope exposed in C9 when incorporated into the terminal complement complex (TCC)